NCT02716571View on ClinicalTrials.gov

Recruiting Blood Donor With Allogeneic Natural Killer Cell

NACompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

March 28, 2016

Primary Completion Date

June 2, 2017

Study Completion Date

July 27, 2017

Conditions
Healthy Volunteers
Interventions
OTHER

Leukapheresis or Plasmapheresis

"Leukapheresis: Donate 5x10\^9 white blood cells and 400 ml of plasma. Plasmapheresis: Donate 400ml of plasma.~Donated white blood cell and plasma will be manufactured MG4101(allogeneic natural killer cell) to use for Hepatocellular carcinoma(HCC) patients after Transarterial Chemoembolization(TACE)."

Trial Locations (1)

03080

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Seoul National University Hospital

OTHER

NCT02716571 - Recruiting Blood Donor With Allogeneic Natural Killer Cell | Biotech Hunter | Biotech Hunter